Fulzerasib vs Glecirasib

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: KRAS G12C · full Non-Small Cell Lung Cancer pipeline

Fulzerasib · Dupert

Marketed by Innovent Biologics under a licence from GenFleet Therapeutics

Phase 2 in Non-Small Cell Lung Cancersmall molecule
Weak signal

NCT05756153 · Phase 1/2 · completed

KROCUS was a single-arm, open-label Phase 1b/2 trial of fulzerasib plus cetuximab in previously untreated KRAS G12C-mutated non-small-cell lung cancer, with 47 patients treated at 30 centres. The Phase 2 primary endpoint was the investigator-assessed objective response rate, and the confirmed rate was 69% (90% CI 56 to 80). With no comparator arm and no formal success threshold reported, no result can be called met or missed. Treatment-related adverse events occurred in 87% of patients, grade 3 in 15%, with no grade 4 or 5 events. The figures come from the final peer-reviewed report (Gregorc et al., Lancet Oncol 2026).

Single-arm response rate with no comparator and no formal statistical threshold.

Next expected readout: March 2027 · NCT07492342 (registry estimate)

Reported efficacy

Phase Ib: adverse events (28 days); Phase II: objective response rate (up to 1 year after last patient in): Confirmed investigator-assessed objective response rate per RECIST 1.1 (Phase 2 primary), fulzerasib 600 mg twice daily plus cetuximab, single arm, first-line KRAS G12C NSCLC: 69% (90% CI 56 to 80); 47 patients treated; data cutoff 14 January 2025. (not_applicable)

Result source: NCT05756153

Glecirasib

Marketed by Allist Pharmaceuticals under a licence from Jacobio Pharmaceuticals

Phase 3 in Non-Small Cell Lung Cancersmall molecule
Weak signal

NCT05002270 · Phase 1/2 · completed

The study was a small, non-randomized, open-label trial without a comparator, evaluating safety, tumor response, and duration of response. Because results are not posted and the design cannot provide a controlled comparison, it offers limited evidence for glecirasib.

Next expected readout: March 2027 · NCT05288205 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointFulzerasibGlecirasib
PFS, median—Trial running · NCT07601048—Trial running · NCT07601048
OS, median—Trial running · NCT07601048—Trial running · NCT07601048
ORR—Trial running · NCT07601048—Trial running · NCT07601048
Duration of response, median—Trial running · NCT07601048—Trial running · NCT07601048

PFS, median

Fulzerasib
—Trial running · NCT07601048
Glecirasib
—Trial running · NCT07601048

OS, median

Fulzerasib
—Trial running · NCT07601048
Glecirasib
—Trial running · NCT07601048

ORR

Fulzerasib
—Trial running · NCT07601048
Glecirasib
—Trial running · NCT07601048

Duration of response, median

Fulzerasib
—Trial running · NCT07601048
Glecirasib
—Trial running · NCT07601048
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Glecirasib: no structured comparison results are available for Non-Small Cell Lung Cancer.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Fulzerasib
Confirmed investigator-assessed objective response rate per RECIST 1.1 (Phase 2 primary), fulzerasib 600 mg twice daily plus cetuximab, single arm, first-line KRAS G12C NSCLC: 69% (90% CI 56 to 80); 47 patients treated; data cutoff 14 January 2025. NCT05756153 · Phase 1/2 · design grade: weak · publication or press release

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Fulzerasib's landscape · Glecirasib's landscape